Acetaminophen for Prevention and Treatment of Organ Dysfunct

This randomized trial assesses whether acetaminophen would increase the number of days alive and free of organ support to day 28 among critically ill

Related Keywords

Massachusetts , United States , San Diego , California , Christopher Seymour , Biomerieux Biomarker , National Institutes Of Health , Kiniksa Pharmaceuticals , Gilead Pharmaceuticals , Protocol Committee , Blood Institute , Genentech , Department Of Defense , Puretech Health , California Institute Of Regenerative Medicine , Amgen , Quantum Health , Denver Health Medical Center , Vanderbilt University Medical Center , Institute Inc , Boehringer Ingelheim , Faron Pharmaceuticals , Blood Institute Prevention , Drug Administration , Group Information , National Heart , Novartis , Sequential Organ Failure Assessment , Oxidative Stress , Early Treatment , Acute Lung Injury , Targeted Therapy , Enhance Recovery , Study Protocol , Major Adverse Kidney Events , Statistical Analysis Plan , Efficacy Outcome , Plasma Cell Free Hemoglobin Levels , Associate Editor , Center North , Interest Disclosures , National Institutes , Global Blood Therapeutics , Virtuoso Surgical , Quantum Leap Healthcare Collaborative , Seastar Biomedical , Direct Biologics , Massachusetts General Hospital , Mass General Brigham , California Institute , Regenerative Medicine ,